Mariner
KRYS icon

Mariner’s Krystal Biotech KRYS Stock Holding History

Mariner’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$401K Buy
1,079
+31
+3% +$9.26K ﹤0.01% 2611
2026
Q1 		$271K Sell
1,048
-3,272
-76% -$871K ﹤0.01% 2956
2025
Q4 		$1.07M Sell
4,320
-285
-6% -$60K ﹤0.01% 1903
2025
Q3 		$813K Buy
4,605
+350
+8% +$52.4K ﹤0.01% 2067
2025
Q2 		$585K Buy
4,255
+618
+17% +$90.8K ﹤0.01% 2204
2025
Q1 		$656K Buy
3,637
+262
+8% +$44.1K ﹤0.01% 1978
2024
Q4 		$529K Sell
3,375
-247
-7% -$43.8K ﹤0.01% 2152
2024
Q3 		$658K Buy
3,622
+325
+10% +$62.7K ﹤0.01% 1923
2024
Q2 		$605K Sell
3,297
-479
-13% -$80.4K ﹤0.01% 1906
2024
Q1 		$672K Buy
3,776
+16
+0.4% +$2.22K ﹤0.01% 1809
2023
Q4 		$466K Sell
3,760
-130
-3% -$14.4K ﹤0.01% 1978
2023
Q3 		$451K Buy
3,890
+64
+2% +$7.81K ﹤0.01% 1850
2023
Q2 		$449K Sell
3,826
-1,124
-23% -$115K ﹤0.01% 1819
2023
Q1 		$396K Sell
4,950
-195
-4% -$15.3K ﹤0.01% 1851
2022
Q4 		$408K Buy
5,145
+1,136
+28% +$84.3K ﹤0.01% 1786
2022
Q3 		$279K Buy
+4,009
New +$290K ﹤0.01% 1824

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Mariner's KRYS Position: Q2 2026 in Review

Mariner increased its Krystal Biotech (KRYS) stake by 3% in Q2 2026, buying an estimated $9.26K and bringing the position to 1,079 shares worth $401K. The position accounts for ﹤0.01% of the portfolio, ranked #2611.

Mariner first reported a position in KRYS in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.07M in Q4 2025. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Mariner held 1,079 shares of Krystal Biotech worth $401K as of Q2 2026.
  • Mariner bought 31 Krystal Biotech shares in Q2 2026, an estimated $9.26K.
  • Krystal Biotech made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2611 holding.
  • Mariner first reported a position in Krystal Biotech in Q3 2022 and has held it in 16 quarters since.
  • Mariner's Krystal Biotech position peaked at $1.07M in Q4 2025.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.